Log in to search using one of your social media accounts:

 

Psychogenic Non-epileptic Seizures and Conversion Disorder Psychogenic Non-epileptic Seizures and Conversion Disorder

Should psychogenic non-epileptic seizures be considered a distinct diagnosis, separate from conversion disorder?Journal of Neurology, Neurosurgery, and Psychiatry
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Related Links:

Condition:   Epilepsy Intervention:   Sponsors:   Epilepsy Foundation of America;   The Epilepsy Study Consortium;   UCB Biopharma S.P.R.L. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
By SAURABH JHA Of my time arguing with doctors, 30 % is spent convincing British doctors that their American counterparts aren’t idiots, 30 % convincing American doctors that British doctors aren’t idiots, and 40 % convincing both that I’m not an idiot. A British doctor once earnestly asked whether American physicians carry credit card reading machines inside their white coats. Myths about the NHS can be equally comical. British doctors don’t prostate every morning in deference to the NHS, like the citizens of Oceania sang to Big Brother in Orwell’s dystopia. Nor, in their daily rounds, do the...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: OP-ED Uncategorized AlfieEvans Source Type: blogs
AbstractLacosamide (Vimpat®) is a functionalized amino acid (available orally and intravenously) approved in the EU and the USA for use as monotherapy and adjunctive therapy for the treatment of focal-onset seizures in adults, adolescents and children aged ≥ 4 years with epilepsy. In adults and adolescents (aged ≥ 16 years), oral lacosamide as adjunctive therapy to other antiepileptic drugs was generally effective in reducing seizure frequency during short-term (up to 18 weeks) treatment, with efficacy sustained over the longer-term (up to 8  years). Moreover, patients were effective...
Source: CNS Drugs - Category: Neurology Source Type: research
Publication date: Available online 21 May 2018 Source:Journal of Clinical Neuroscience Author(s): Kaijia Yu, Chang Liu, Tao Yu, Xueyuan Wang, Cuiping Xu, Duanyu Ni, Yongjie Li The authors present a case of an out-of- body experience (OBE) that occurred in a child with intractable epilepsy when stimulating the anterior insular cortex (AIC) by intracranial electrodes. After destroying several sites precisely located at the left AIC by radiofrequency thermocoagulation, the patient’s seizures disappeared, and the OBE could not be reproduced when repeatedly stimulating these sites. To our knowledge, it has never been rep...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research
Discussion: Residue G1306 Neonatal laryngospasm and unusual distribution of myotonia, muscle hypertrophy, and weakness encourage direct search for the G1306E mutation, a hotspot for de-novo mutations. Successful therapy with the sodium channel blocker flecainide is due to stabilization of the inactivated state and special effectiveness for enlarged window currents. Our G1306E collection is the first genetically clarified case series from newborn period to adulthood and therefore helpful for counselling. PMID: 29774303 [PubMed - in process]
Source: Acta Myologica - Category: Neurology Tags: Acta Myol Source Type: research
Conclusions: In this review we will provide animal and human research data on the current clinical neurological uses for CBD individually and in combination with Δ9-THC. We will emphasize the neuroprotective, antiinflammatory, and immunomodulatory benefits of phytocannabinoids and their applications in various clinical syndromes. PMID: 29770251 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Authors: Wang B, Gupta G, Singh M, Veerabhadrappa KVS, Mishra A, Chinnaboina GK Abstract The present study was designed to explore the effect of chronic administration of a new flavone [morusflavone, 5,7,4'-trihydroxy-8-(γ,γ-dimethylallyl)-2',3'-(10'-hydroxy-9',10'-dimethyl-cyclohex-8-enyl)-flavone (compound 1)] at doses of 25, 50, and 100 mg/kg, orally (p.o.) to pentylenetetrazole-induced kindling in rats (a model of human epilepsy). Compound 1 and four other compounds were isolated from the stem bark of Morus alba. The structure of compound 1 was elucidated and established using standard spectroscopic...
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research
More News: Brain | Epilepsy | Health | Neurology | Neurosurgery | Psychiatry